Randomized Double-blind Trials of Jingyuankang Capsule on Peripheral Blood Leukocyte in HIV/AIDS Cases JIANG Shi\|qing, SUN Hong\|xin, XU Ying\|min, PEI Jun\|wen, WANG Hong\|ling
|更新时间:2024-09-23
|
Randomized Double-blind Trials of Jingyuankang Capsule on Peripheral Blood Leukocyte in HIV/AIDS Cases JIANG Shi\|qing, SUN Hong\|xin, XU Ying\|min, PEI Jun\|wen, WANG Hong\|ling
Chinese Journal of Experimental Traditional Medical FormulaeVol. 16, Issue 14, Pages: 201-203(2010)
作者机构:
作者简介:
基金信息:
DOI:
CLC:
Published:2010
稿件说明:
移动端阅览
JIANG Shi-qing, SUN Hong-xin, XU Ying-min, et al. Randomized Double-blind Trials of Jingyuankang Capsule on Peripheral Blood Leukocyte in HIV/AIDS Cases JIANG Shi\|qing, SUN Hong\|xin, XU Ying\|min, PEI Jun\|wen, WANG Hong\|ling[J]. Chinese journal of experimental traditional medical formulae, 2010, 16(14): 201-203.
DOI:
JIANG Shi-qing, SUN Hong-xin, XU Ying-min, et al. Randomized Double-blind Trials of Jingyuankang Capsule on Peripheral Blood Leukocyte in HIV/AIDS Cases JIANG Shi\|qing, SUN Hong\|xin, XU Ying\|min, PEI Jun\|wen, WANG Hong\|ling[J]. Chinese journal of experimental traditional medical formulae, 2010, 16(14): 201-203.DOI:
Randomized Double-blind Trials of Jingyuankang Capsule on Peripheral Blood Leukocyte in HIV/AIDS Cases JIANG Shi\|qing, SUN Hong\|xin, XU Ying\|min, PEI Jun\|wen, WANG Hong\|ling
Objective: To observe the the therapeutic effect on peripheral blood leukocyte reduction of AIDS by Jingyuankang Capsule. Method: 116 cases of HIV/AIDS patients were divided into two groups: 58 cases in the treatment were treated by Jingyuankang Capsule and likejun mimic tablet with HAART therapy
and the other 58 cases in the control by likejun tablet and mimic Jingyuankang Capsules with HAART. The design was a randomized double-blind research
and 6 months as a course. Peripheral blood leukocytes were monitored for these cases. Result: Jingyuankang Capsule treatment for AIDS showed good effect
whether they had taken with AZT (HAART) or not. HAART scheme showed that it could improve peripheral blood leukocytes. Jingyuankang Capsule appeared safe and effective. Through clinical investigation and follow-up the capsule showed no toxicity and adverse reaction. Conclusion: Jingyuankang Capsules can effectively treat AIDS patients with reduction in peripheral blood leukocyte.